Shandin A N, Peterkova V A
Endocrinology Research Centre.
Probl Endokrinol (Mosk). 2009 Aug 15;55(4):36-44. doi: 10.14341/probl200955436-44.
Idiopathic short stature is the low stature in which all possible causes are excluded. The diagnosis and treatment of idiopathic short stature are the subject of constant controversy and discussion. With the expansion of indications for growth hormone therapy for conditions unaccompanied by growth hormone deficiency, there has been recently a challenge as to its use in idiopathic short stature. To date, there has been much worldwide evidence for the efficiency and safety of growth hormone therapy in children with idiopathic short stature. In 2008, the International consensus on the diagnosis and management of idiopathic short stature, prepared through the joint collaboration of three research societies: the Growth Hormone Society, the Lowson Wilkins Society of Pediatric Endocrinology (USA), and the European Society of Pediatric Endocrinology. The main points of this document have formed the basis for this paper.
特发性矮小症是指排除了所有可能病因后的身材矮小。特发性矮小症的诊断和治疗一直是备受争议和讨论的话题。随着生长激素治疗适应证扩展至非生长激素缺乏的情况，近期其在特发性矮小症中的应用面临挑战。迄今为止，全球有大量证据表明生长激素治疗对特发性矮小症患儿有效且安全。2008年，由生长激素协会、美国劳森·威尔金斯儿科内分泌学会和欧洲儿科内分泌学会这三个研究学会联合协作制定了关于特发性矮小症诊断和管理的国际共识。本文以此文件的要点为基础。
